We found that for 26 KEGG pathways (up-regulated = 12, down-regulated = 14; see Table 2), the magnitude of differential expression (CRC tissue vs. normal tissue) was significantly greater in the presence of KRAS mutation (ANOVA interaction p < 0.05, see Table 2). This evidence concerns the gene KRAS and colorectal carcinoma.